Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS: We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either ATRA plus arsenic trioxide for induction and consolidation therapy or standard ATRA-idarubicin induction therapy followed by three cycles of consolidation therapy with ATRA plus chemotherapy and maintenance therapy with low-dose chemotherapy and ATRA. The study was designed as a noninferiority trial to show that the difference between the rates of event-free survival at 2 years in the two groups was not greater than 5%. RESULTS: Complete remission was achieved in all 77 patients in the ATRA-arsenic trioxide group who could be evaluated (100%) and in 75 of 79 patients in the ATRA-chemotherapy group (95%) (P=0.12). The median follow-up was 34.4 months. Two-year event-free survival rates were 97% in the ATRA-arsenic trioxide group and 86% in the ATRA-chemotherapy group (95% confidence interval for the difference, 2 to 22 percentage points; P<0.001 for noninferiority and P=0.02 for superiority of ATRA-arsenic trioxide). Overall survival was also better with ATRA-arsenic trioxide (P=0.02). As compared with ATRA-chemotherapy, ATRA-arsenic trioxide was associated with less hematologic toxicity and fewer infections but with more hepatic toxicity. CONCLUSIONS: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL. (Funded by Associazione Italiana contro le Leucemie and others; ClinicalTrials.gov number, NCT00482833.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Self-citationShen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
van Dongen, J., Macintyre, E., Gabert, J., Delabesse, E., Rossi, V, Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401592 · Cited by 1,169
Self-citationSanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationUnited States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826 · cited 1×
“A genetic diagnosis could be established by detection of the PML-RARA fusion gene by means of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay,28,29 demonstration of the t(15;17) translocation by means of conventional karyotyping or fluorescence in situ hybridization (FISH),30 or evidence of a microspeck…”
Research works printed but not linked: 3
- Zhang P, 1996, Chin J Hematol, 17, 58
- Sanz MA, 2000, Blood, 96, 1247
- Grimwade D, 2000, Blood, 96, 1297
Cited by
Items 601–700 of 1,000
Precision medicine in acute myeloid leukemia: Hope, hype or both?
Prasad, V. K., & Gale, R. P. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.07.011 · Cited by 18
Koury, L. C. A., Ganser, A., Berliner, N., & Rego, E. M. (2017) · British Journal of Haematology · doi:10.1111/bjh.14589 · Cited by 15
“…on recent clinical studies demonstrating that arsenic trioxide in combination with ATRA provides comparable and perhaps superior results compared to ATRA and chemotherapy and may become the new standard of care in this disease, at least for low-intermediate risk patients (Lo-Coco et al, 2013).”
ResultSelf-citationOutpatient Oral Treatment for Acute Promyelocytic Leukemia
Zhu, H., & Huang, X. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1500125 · Cited by 15
p53 as an Effector or Inhibitor of Therapy Response
Ablain, J., Poirot, B., Esnault, C., Lehmann-Che, J., & de Thé, H. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026260 · Cited by 15
Hourmant, Y., Kouatchet, A., López, R., Mokart, D., Pène, F., Mayaux, J., Bruneel, F., Lebert, C., Renault, A., Meert, A., et al. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.10.022 · Cited by 14
“outcome, changes in therapeutic options, including intensive chemotherapy [9], biotherapy, targeted therapy [10,11] and cellular therapies with CAR-T cells [12] have considerably improved chances to obtain event free survival [13,14].”
BackgroundMethodChin, L., Kumana, C. R., Kwong, Y., & Gill, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091945 · Cited by 17
“In total after third consolidation, 115 patients went through PCR in the ATRA-ATO arm with 100% being PCR negative for the PML::RARA transcript and out of 119 patients in the ATRA-chemotherapy arm 117 were PCR negative [94,95].”
BackgroundMethodFeng, L., Zhang, P. Y., Gao, W., Yu, J., & Robson, S. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1244280 · Cited by 22
“While 95% cure rate is expected in younger patients with non-high-risk acute promyelocytic leukemia, this is essentially incurable for older adults with refractory or resistant disease, such as in the case of complex karyotypes (12, 13).”
BackgroundTsai, H. K., Sabbagh, M. F., Montesion, M., Williams, E. A., Arbini, A., Boué, D. R., Harris, E. M., Wachter, F., Grimmett, L., Place, A. E., et al. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100509 · Cited by 18
Chen, Z., Tong, Y., Li, Y., Qingping, G., Wang, Q., Fu, C., & Xia, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122530 · Cited by 14
“Once patients were identified as APL, BM samples during follow-up were requested for RT-qPCR analysis after induction and 3 cycles of consolidation therapy according to the treatment protocol [15,21] and International APL Guideline [4].”
MethodMarchwicka, A., Corcoran, A., Berkowska, K., & Marcinkowska, E. (2016) · Cell & Bioscience · doi:10.1186/s13578-016-0075-9 · Cited by 15
“However, at present the clinical success of differentiation therapy for AML is limited to one rare subtype, which can be cured using all-trans retinoic acid (ATRA) [11].”
BackgroundThulasiraman, P., Garriga, G., Danthuluri, V., McAndrews, D. J., & Mohiuddin, I. Q. (2017) · Oncology Reports · doi:10.3892/or.2017.5495 · Cited by 16
Liang, B., Zheng, Z., Shi, Y., Chen, J., Hu, X., Qian, H., Shen, Z., Jiang, S., Yu, K., & Feng, J. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s135013 · Cited by 14
Negative regulation of miR‐1275 by H3K27me3 is critical for glial induction of glioblastoma cells
Mai, J., Gu, J., Liu, Y., Liu, X., Sai, K., Chen, Z., Lu, W., Yang, X. T., Wang, J., Guo, C., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12525 · Cited by 15
Structural Variants as a Basis for Targeted Therapies in Hematological Malignancies
Schütte, J., Reusch, J., Khandanpour, C., & Eisfeld, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00839 · Cited by 14
“Eventually, the replacement of chemotherapy by arsenic trioxide (ATO) in combination with ATRA in frontline therapy led to outstanding survival rates with remarkable reduction of chemotherapyrelated toxicity (61).”
BackgroundNovel Mechanistic Insights into the Anti-cancer Mode of Arsenic Trioxide
Wahiduzzaman, M., Ota, A., & Hosokawa, Y. (2019) · Current Cancer Drug Targets · doi:10.2174/1568009619666191021122006 · Cited by 15
Kampa-Schittenhelm, K. M., Haverkamp, T., Bonin, M., Tsintari, V., Bühring, H., Haeusser, L. A., Blumenstock, G., Dreher, S., Ganief, T. A., Akmut, F., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102678 · Cited by 15
“Most therapies in oncology aim to (more or less selectively) kill the malignant cells however, the most successful mode-of-action has been demonstrated in APL via overriding the differentiation blockage of the initiating leukemic clone leading to cure of this highly aggressive malignancy [4].”
BackgroundInfluentialXiang, J., Chi, Y.-Y., Han, J.-X., Xiang, H., & Xie, Q. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x21500038 · Cited by 15
Zheng, Y., Mao, Y., Zhao, H., Chen, L., Wang, L., Zhang, Y.-X., Hu, J., Li, J., Li, X., & Zhu, H. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00205-6 · Cited by 14
“[3] reported that the incidence of grade 3–4 liver dysfunction in the ATRA + ATO group was even up to 57%.”
BackgroundResultDing, W., Weng, G., Wang, Z., Guo, Y., Wang, M., Shen, H., Chen, S., Du, X., & Wen, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1028651 · Cited by 14
“The majority of APL is characterized by a t(15;17) translocation resulting in the PML::RARA fusion gene, which is sensitive to therapy with alltrans retinoic acid (ATRA) (1).”
BackgroundInfluentialShen, X., Zhi, F., Shi, C., Xu, J., Chao, Y., Xu, J., Jiang, Y., Bai, Y., & Yang, B. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03895-0 · Cited by 14
“Introduction Arsenic trioxide (ATO) is an important clinical therapeutic drug for leukemia [1] and liver cancer [2, 3], which also has therapeutic potential for breast cancer [4, 5], lung cancer [6, 7], and gastric cancer [8, 9], etc.”
How could patient reported outcomes improve patient management in chronic myeloid leukemia?
Marchi, F. D., Medeot, M., Fanin, R., & Tiribelli, M. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2017.1262758 · Cited by 15
“emerging as standard induction therapy [34].”
Anti-liver cancer effect and the mechanism of arsenic sulfide in vitro and in vivo
Wang, S., Zhang, C., Li, Y., Li, P., Zhang, D., & Li, Z. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3755-9 · Cited by 14
Liang, K., Bae, K. H., Niibori-Nambu, A., Dutta, B., Chung, J. E., Osato, M., & Kurisawa, M. (2019) · Biomaterials Science · doi:10.1039/c9bm01146c · Cited by 15
Cardiovascular events in cancer survivors
Howard, E., Steingart, R. M., Armstrong, G. T., Lyon, A. R., Armenian, S. H., Voso, M. T., Cicconi, L., Lo‐Coco, F., & Minotti, G. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.01.007 · Cited by 14
Self-citationCampelj, D. G., Timpani, C. A., & Rybalka, E. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12880 · Cited by 13
“successful, particularly in the AML subtype, acute promyelocytic leukaemia, through the identification of a novel gene therapy, which proffers improved survivability.(121) Despite the clinical utility of risk stratification based on cytogenetics, patients in each cytogenetic risk group remain prognostically heterogene…”
BackgroundNanozymes: a new approach for leukemia therapy
Wang, W., An, J., Zhao, R., Geng, X., Jiang, W., Yan, X., & Jiang, B. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02819d · Cited by 15
Hierarchical self-recognition and response in CSC and non-CSC micro-niches for cancer therapy
Yang, Y., Peng, Y., Du, Y., Lin, M. S., Li, J., Gao, D., Yang, Z., Wang, W., Zhou, Y., Li, X., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122581 · Cited by 14
Function of PML-RARA in Acute Promyelocytic Leukemia
Testa, U., & Pelosi, E. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-62731-6_14 · Cited by 19
Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia
Zhang, Y., Che, N., Wang, S., Meng, J., Zhao, N., Han, J., Dong, X., Li, Y., Mo, J., Zhao, X., et al. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02140-9 · Cited by 14
Jaffray, E., Tatham, M. H., Mojsa, B., Plechanovová, A., Rojas‐Fernández, A., Liu, J. C. Y., Mailand, N., Ibrahim, A. F. M., Ball, G., Porter, I. M., et al. (2025) · The Journal of Cell Biology · doi:10.1083/jcb.202407133 · Cited by 13
Chen, Y., Zhao, N., Xu, L., Jia, X., Liu, F., Huang, J., Li, X., Wang, Y., Lai, C., Shen, Y., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02359-x · Cited by 15
“Notably, ATRA is the standard therapy for acute promyelocytic leukemia as a differentiation inducer [60, 61].”
Song, X., Hu, X., Lü, S., Gao, L., Chen, L., Yang, J., Zhang, W., & Wang, J. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12301 · Cited by 13
“Lo-Coco (30) 77 ATRA+ATO 100 NA NA 99% (2 yr) 97% (2 yr)”
BackgroundTreatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions
Lengfelder, E., Hofmann, W., & Nowak, D. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.833681 · Cited by 14
Singh, Z. N., Duong, V. H., Koka, R., Zou, Y. S., Sawhney, S., Tang, L., Baer, M. R., Ambulos, N. P., Chaer, F. E., & Emadi, A. (2018) · Journal of Hematopathology · doi:10.1007/s12308-018-0329-z · Cited by 13
Ciangola, G., Gurnari, C., Paterno, G., Mirabile, M., Angelini, M., Lavorgna, S., Ottone, T., Travaglini, S., Cicconi, L., & Lo‐Coco, F. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.01.004 · Cited by 13
Self-citationOptimizing management of acute leukemia in community centers and when to refer
Jillella, A. P., Cortes, J. E., & Kota, V. K. (2020) · Hematology · doi:10.1182/hematology.2020000096 · Cited by 14
Sun, D., & Wang, S. (2021) · Oncology Letters · doi:10.3892/ol.2021.12842 · Cited by 13
Drug treatment options for acute promyelocytic leukemia
Ferrara, F., Molica, M., & Bernardi, M. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1961744 · Cited by 15
“This event can be potentially fatal leading to torsade de pointes-type ventricular arrhythmia [23].”
BackgroundMethodSelf-citationWang, C., Wang, Y., Zuo, N., Fang, S., & Shi, J. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022006980 · Cited by 13
Zhang, Z., Zhang, S., Zhang, F., Zhang, Q., Wei, H., Xiu, R., Zhao, Y., & Sui, M. (2023) · Biological Trace Element Research · doi:10.1007/s12011-023-03676-2 · Cited by 13
“It has been reported that regimens with ATO have a higher incidence of hepatotoxicity than regimens without ATO when used for the treatment of APL [4].”
BackgroundJung, Y. S., Cheong, H.-J., Kim, S.-J., Kim, K. H., Lee, N.-S., Park, H. S., & Won, J.-H. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.05.019 · Cited by 13
Zeidan, A. M., & Gore, S. D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2725 · Cited by 13
“The distinct but complementary mechanisms of action of ATOandATRAprovided a biologic rationale for combining the two agents to achieve synergistic efficacy with low toxicity (43).”
BackgroundMethodPARP inhibitors: a treatment option for AML?
Wang, L., Hamard, P.-J., & Nimer, S. D. (2015) · Nature Medicine · doi:10.1038/nm.4007 · Cited by 13
Heiblig, M., Jeune, C. L., Elhamri, M., Balsat, M., Tigaud, I., Pleșa, A., Barraco, F., Labussière, H., Ducastelle, S., Nicolini, F. E., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1180688 · Cited by 13
“Long-term survival was 83% in APL patients, which should certainly benefit from a nonchemotherapy therapy based on ATRA and arsenic trioxide combination in a near future.[27] Our study has certainly several major limitations.”
BackgroundDifferentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies
Norsworthy, K. J., Cho, E., Arora, J. K., Kowalski, J., Tsai, H., Warlick, E. D., Showel, M. M., Pratz, K. W., Sutherland, L., Gore, S. D., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.09.003 · Cited by 15
Kumar, S., Brown, A. M., & Tchounwou, P. B. (2018) · Oncotarget · doi:10.18632/oncotarget.26025 · Cited by 13
“It is also best suited for older and cardiovascular disease-complicated APL patients [20].”
BackgroundNovel tumor‑suppressor FOXN3 is downregulated in adult acute myeloid leukemia
He, H., Zhang, J., Qu, Y., Wang, Y., Zhang, Y., Yan, X., Li, Y., & Zhang, R. (2019) · Oncology Letters · doi:10.3892/ol.2019.10424 · Cited by 15
Chen, J., Tian, B., Zhou, C., Sun, J., Li, L., Jin, S., Liu, Q., Fu, S., Liu, L., Liu, H., et al. (2019) · Journal of Cancer · doi:10.7150/jca.34506 · Cited by 14
“ATO is thus considered the 'gold partner' of retinoic acid [12,13].”
BackgroundChen, X., Hong, Y., Zheng, P., You, X., Feng, J., Huang, Z., & Wang, Y. (2019) · Cancer · doi:10.1002/cncr.32519 · Cited by 13
“Utilities of AEs derived after conducting a literature review of published utility values associated with cancer treatment-related AEs, along with weighted-average disutilities, were adopted for the same AE and were considered no utility loss for patients who had a QTc interval prolongation or hepatotoxicities because…”
BackgroundMethodInfluentialSaxena, K., & Konopleva, M. Y. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1804856 · Cited by 14
Autore, F., Chiusolo, P., Sorà, F., Giammarco, S., Laurenti, L., Innocenti, I., Metafuni, E., Piccirillo, N., Pagano, L., & Sica, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.614721 · Cited by 13
“The use of ATO and ATRA showed excellent results in terms of CR and long-term leukemia free survival (11, 12).”
BackgroundSelf-citationZhang, Y., Wu, S., Luo, D., Zhou, J., & Li, D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147545 · Cited by 13
“The results showed that the non-chemotherapy dual-differentiation agents for induction and consolidation therapy were superior to chemotherapy regimen in both two-year event-free and overall survival rates in patients with low-to-intermediate-risk APL [12].”
BackgroundResultBret, C., Viziteu, E., Kassambara, A., & Moreaux, J. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1141673 · Cited by 15
“retinoic acid receptor alpha (RARA) fusion [22,23].”
da Rosa, F. C., Pardinho, R. B., Moreira, M. E. S., de Souza, L. G. T., Flores, É. M. M., Mortari, S. R., & Dressler, V. L. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.11.008 · Cited by 13
Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age
Finsinger, P., Breccia, M., Minotti, C., Carmosino, I., Girmenia, C., Chisini, M., Volpicelli, P., Vozella, F., Romano, A., Montagna, C., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2197-7 · Cited by 12
Self-citationEfficace, F., Mandelli, F., Platzbecker, U., Cottone, F., & Lo‐Coco, F. (2015) · Blood · doi:10.1182/blood-2015-07-658922 · Cited by 12
Self-citationHigher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer
Velcheti, V., Radivoyevitch, T., & Saunthararajah, Y. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_174175 · Cited by 12
Collinge, E., Tigaud, I., Balme, B., Gerland, L., Sujobert, P., Carlioz, V., Salles, G. A., Thomas, X., & Paubelle, É. (2018) · Medicine · doi:10.1097/md.0000000000009657 · Cited by 12
“15 mg/kg/day) was initiated according to the schedule recently published by Lo-Coco et al.([2]) After 10 days of treatment, a discharge of pus appeared at the center of the cutaneous lesion (Fig.”
InfluentialUeda, M., Stefan, T., Stetson, L. C., Ignatz-Hoover, J. J., Tomlinson, B. K., Creger, R. J., Cooper, B., Lazarus, H. M., Lima, M. J. G. D., Wald, D. N., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00327 · Cited by 12
“Such differentiation therapy has proven successful in the treatment of acute promyelocytic leukemia (1) but not in other AML subtypes.”
BackgroundMethodA carboxylic acid isostere screen of the DHODH inhibitor Brequinar
DeRatt, L. G., Pietsch, E. C., Tanner, A., Shaffer, P. L., Jacoby, E., Wang, W., Kazmi, F., Zhang, X., Attar, R. M., Edwards, J. P., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127589 · Cited by 12
Fusion Oncoproteins in Childhood Cancers: Potential Role in Targeted Therapy
Angione, S. D. A., Akalu, A. Y., Gartrell, J., Fletcher, E. P., Burckart, G. J., Reaman, G. H., Leong, R., & Stewart, C. F. (2021) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-26.6.541 · Cited by 13
Emerging 2D pnictogens for biomedical applications
Li, R., Zha, Z., Miao, Z., & Xu, C. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.09.062 · Cited by 13
Bewersdorf, J. P., Prozora, S., Podoltsev, N. A., Shallis, R. M., Huntington, S. F., Neparidze, N., Wang, R., Zeidan, A. M., & Davidoff, A. J. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005642 · Cited by 12
Bamberg, L. V., Heigwer, F., Wandmacher, A. M., Singh, A. P., Betge, J., Rindtorff, N., Werner, J., Josten, J., Skabkina, O., Hinsenkamp, I., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34155 · Cited by 13
“Examples for the successful clinical application of synthetic lethality include the use of PARP inhibitors in BRCAdeficient cancers(11) and the combination of all-trans retinoic acid and arsenic trioxide for the treatment of promyelocytic leukemia.(12) In this context, functional genomics screens using CRISPR/Cas have…”
BackgroundJiang, M., Li, J., Wu, J., Zhu, Y., & Gao, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1028089 · Cited by 12
“APL has become the subtype of AML with the highest cure rate, the longterm survival rate being 95% and above (2).”
BackgroundCanevarolo, R. R., Melo, C. P. D. S., Cury, N. M., Artico, L. L., Corrêa, J. R., Lau, Y. T., Mariano, S. D. S., Sudalagunta, P. R., Brandalise, S. R., Zeri, A. C. D. M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1032336 · Cited by 12
“Both auranofin and ATO — a rheumatologic and a chemotherapy agent, respectively — potentiated MTX cytotoxicity slightly in a few cell lines, indicating that the thioredoxin antioxidant system could be protecting the cells from the oxidative stress caused by MTX. ATO has been used against acute promyelocytic leukemia (…”
MethodEigenschink, M., Bellach, L., Leonard, S. R., Dablander, T. E., Maier, J., Dablander, F., & Sitte, H. H. (2023) · BMJ Open · doi:10.1136/bmjopen-2021-060644 · Cited by 16
Exploring the nexus of nuclear receptors in hematological malignancies
Manickasamy, M. K., Sajeev, A., BharathwajChetty, B., Alqahtani, M. S., Abbas, M. A. E., Hegde, M., Aswani, B. S., Shakibaei, M., Sethi, G., & Kunnumakkara, A. B. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05085-z · Cited by 12
Mannis, G. N., Logan, A. C., Leavitt, A. D., Yanada, M., Hwang, J. H., Olin, R. L., Damon, L. E., Andreadis, C. B., Ai, W. Z., Gaensler, K. M. L., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.201 · Cited by 12
BCL-xL/MCL-1 inhibition and RARγ antagonism work cooperatively in human HL60 leukemia cells
Perri, M., Yap, J. L., Yu, J., Cione, E., Fletcher, S., & Kane, M. A. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.07.024 · Cited by 12
Dose‐adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure
Firkin, F. C., Roncolato, F., & Ho, W. K. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12502 · Cited by 12
“02), to that obtained with ATRA and chemotherapy in the alternative treatment arm that had previously been regarded to be the standard of care (6).”
Wang, F., Jia, J., Wang, J., Zhao, T., Jiang, Q., Jiang, H., & Zhu, H. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.09.006 · Cited by 12
Clinical Manifestations and Treatment of Acute Myeloid Leukemia
Faderl, S., & Kantarjian, H. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00059-7 · Cited by 15
Lou, Y., Lu, Y., Zhu, Z., Ma, Y., Suo, S., Wang, Y., Chen, D., Tong, H., Qian, W., Meng, H., et al. (2018) · Hematological Oncology · doi:10.1002/hon.2519 · Cited by 12
“The ATRA plus ATO chemotherapy‐free protocol has been the preferred regimen since Lo‐Coco et al reported the data in 2013.(5) Patients received therapy at the discretion of the treating physician and patient preference.”
MethodHambley, B. C., Norsworthy, K. J., Jasem, J. A., Zimmerman, J. W., Shenderov, E., Webster, J. A., Showel, M. M., Gondek, L. P., Dalton, W. B., Prince, G. T., et al. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.106174 · Cited by 13
Zhang, Y., Wang, L., Zhang, R., Qi, P., Xie, J., Shi, H., Lin, W., Wu, Y., Yu, J., Fan, J., et al. (2019) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2019.1621971 · Cited by 12
“Further reductions in cytotoxic chemotherapy may be possible using the ATO- and ATRA-based therapy as demonstrated in pediatric APL population.(28,29) It was shown in particular in two large randomized trials that the combination of ATO and ATRA without chemotherapy was at least equal, and with longer-term follow-up,…”
MethodSasijareonrat, N., Jahn, N., Ungprasert, P., & Owattanapanich, W. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820937008 · Cited by 13
“Median platelets, 10(9)/L (range) 29 (5-333) 31 (5-164) 36 (6-179) 40 (8-165) 17 (4-226) 23 (4-82) 30 (18-60) 25 (12-48)”
Pereira‐Martins, D. A., Weinhäuser, I., Coelho‐Silva, J. L., Franca-Neto, P. L., Almeida, L. Y., Bianco, T. M., Silva, C. L., França, R. F. D. O., Traina, F., Rego, E. M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03604-z · Cited by 12
Liu, W., Wang, B., Zhao, Y., Wu, Z., Dong, A., Chen, H., Lin, L., Lu, J., & Hai, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.647687 · Cited by 12
“Previous studies have suggested that appropriate dosage can reduce the incidence of potential adverse effects (Lo-Coco et al., 2013; Gill et al., 2018; Kumana et al., 2020), and proposed several possible mechanisms of organ toxicity, including the promotion of oxidative damage, disturbance of ion channel balance, alte…”
BackgroundArsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia
Zacholski, K., Hambley, B. C., Hickey, E., Kashanian, S. M., Li, A. Y., Baer, M. R., Duong, V. H., Newman, M. J., Dezern, A. E., Gojo, I., et al. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211024727 · Cited by 12
“cardiac dysfunction and secondary malignancies).(2,3) However, patients receiving ATO may still experience clinically significant complications during treatment, including hepatotoxicity, QTc prolongation, neurotoxicity, and myelosuppression.”
BackgroundHunger, S. P., Teachey, D. T., Grupp, S. A., & Aplenc, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00093-1 · Cited by 19
Miyata, K., Yotsumoto, F., Nam, S. O., Odawara, T., Manabe, S., Ishikawa, T., Itamochi, H., Kigawa, J., Takada, S., Asahara, H., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.301 · Cited by 12
“plus other chemotherapy [37].”
Chlapek, P., Neradil, J., Rédová, M., Zitterbart, K., Štěrba, J., & Veselská, R. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-51 · Cited by 14
“The enhancing effects of these modulators were described in several clinical trials focused on the treatment of leukemia [13-16]; they were also demonstrated under in vitro conditions using tumor cells of a neurogenic origin [17-20].”
BackgroundArsenic trioxide augments all-trans retinoic acid-induced differentiation of HL-60 cells
Sumi, D., Suzukawa, K., & Himeno, S. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.02.054 · Cited by 13
Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia
Zhang, X., & Pan, J. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2923-z · Cited by 12
Hattori, H., Ishikawa, Y., Kawashima, N., Akashi, A., Yamaguchi, Y., Harada, Y., Hirano, D., Adachi, Y., Miyao, K., Ushijima, Y., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204850 · Cited by 12
Yu, Q., Wang, P., Yang, L., Wu, Z., Li, S., Xu, Y., Wu, B., Ma, A., Gan, X., & Xu, R. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109134 · Cited by 12
Cancer drugs and QT prolongation: weighing risk against benefit
Menna, P., Salvatorelli, E., & Minotti, G. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1354987 · Cited by 12
“In the trial of ATO for the treatment of newly diagnosed lowintermediate risk APL, Framingham-corrected long QT was detected in 16% of patients [15].”
BackgroundMuluneh, B., Richardson, D. R., Hicks, C. H., Jensen, B. C., & Zeidner, J. F. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00922 · Cited by 12
Management of Acute Promyelocytic Leukemia at Extremes of Age
Käyser, S., & Conneely, S. E. (2023) · Cancers · doi:10.3390/cancers15143637 · Cited by 13
“In the case of grade 3/4 non-hematological toxicities during treatment with ATO/ATRA, dose modifications, according to Table 2, are recommended [10,11].”
BackgroundMethodResultInfluentialWu, Q. Z., Yang, X., Zhang, J.-R., Xue, M., Dou, X., Ge, Z., Chen, Y., Gu, W., Dong, W., Cao, H., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01074-y · Cited by 11
“To the Editor, With the introduction of differentiating agents, such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), the outcomes of patients with acute promyelocytic leukemia (APL) have signi fi - cantly improved [1, 2].”
BackgroundMaity, A., Sathyanarayanan, A., Kumar, R. C., Vora, J., Gawde, J., Jain, H., Bagal, B. P., Subramanian, P. G., Sengar, M., Khattry, N., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014539 · Cited by 11
“24 Although ~90% of APL cases harbor the bcr1 and bcr3 isoforms, identi fi cation of all 3 isoforms (bcr1, bcr2, and bcr3) at diagnosis is essential to predict any impending relapse by RQ-PCR during follow-up.”
Jillella, A. P., Lee, S. J., Altman, J. K., Luger, S. M., Tallman, M. S., Foran, J. M., Bradshaw, D., Law, L. Y., Bryan, L. J., Zahr, A. A., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2024.7033 · Cited by 13
CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias
Fleming, T. J., Antoszewski, M., Lambo, S., Gundry, M. C., Piussi, R., Wahlster, L., Shah, S. B., Reed, F. E., Dong, K. D., Paulo, J. A., et al. (2025) · Blood · doi:10.1182/blood.2025028954 · Cited by 13
Nichol, J. N., Garnier, N. M., & Miller, W. H. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.04.009 · Cited by 12
“A recent phase III clinical trial, comparing the efficacy of RA in combination with ATO versus ATRA in combination with idarubicin has shown that RA in combination with ATO is at least as efficient as RA in combination with idarubicin [69].”
BackgroundFighting against hematological malignancy in China: from unique system to global impact
Lv, M., & Huang, X. (2015) · Science China Life Sciences · doi:10.1007/s11427-015-4926-0 · Cited by 11
Zhang, L., Yang, X., Chen, J., Hu, L., Yang, F., Zhou, Y., Zhao, B., Zhao, W., & Zhu, X. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s305244 · Cited by 11
Perez, J. M. R., Patel, K. P., Loghavi, S., Garcia‐Manero, G., Borthakur, G. M., Jabbour, E. J., Wierda, W. G., Pierce, S. A., Brandt, M., Kornblau, S. M., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1992757 · Cited by 11
Gianni’, M., Goracci, L., Schläfli, A. M., Veroli, A. D., Kurosaki, M., Guarrera, L., Bolis, M., Foglia, M., Lupi, M., Tschan, M. P., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-021-04476-z · Cited by 11
At What Point Are Long-Term (>5 Years) Survivors of APL Safe? A Study from the SEER Database
Yin, X., Wang, R., Shen, H., Jin, J., & Zhu, H. (2023) · Cancers · doi:10.3390/cancers15030575 · Cited by 11
“Another study also showed that hepatotoxicity, especially complications of increased liver enzymes (mainly AST and ALT and less commonly alkaline phosphatase and bilirubin), may occur in up to 60% of cases receiving APL treatment [31].”
Background
Metadata
- Authors
- Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., Specchia, G., Sica, S., Divona, M., Levis, A., Fiedler, W., Cerqui, E., Breccia, M., Fioritoni, G., Salih, H. R., Cazzola, M., Melillo, L., Carella, A. M., Brandts, C. H., Morra, E., von Lilienfeld-Toal, M., Hertenstein, B., Wattad, M., Lübbert, M., Hänel, M., Schmitz, N., Link, H., Kropp, M. G., Rambaldi, A., La Nasa, G., Luppi, M., Ciceri, F., Finizio, O., Venditti, A., Fabbiano, F., Döhner, K., Sauer, M., Ganser, A., Amadori, S., Mandelli, F., Döhner, H., Ehninger, G., Schlenk, R. F., & Platzbecker, U.
- ORCID
- Avvisati, Giuseppe
- Vignetti, Marco
- Thiede, Christian
- Iacobelli, Simona
- Ferrara, Felicetto
- Fazi, Paola
- Cicconi, Laura
- Specchia, Giorgina
- Sica, Simona
- Fiedler, Walter
- Breccia, Massimo
- Salih, Helmut R.
- Cazzola, Mario
- Melillo, Lorella
- Carella, Angelo M.
- Brandts, Christian H.
- Hertenstein, Bernd
- Lübbert, Michael
- Hänel, Matthias
- Schmitz, Norbert
- Link, Hartmut
- Rambaldi, Alessandro
- Luppi, Mario
- Ciceri, Fabio
- Finizio, Olimpia
- Venditti, Adriano
- Döhner, Konstanze
- Ganser, Arnold
- Amadori, Sergio
- Döhner, Hartmut
- Ehninger, Gerhard
- Schlenk, Richard F.
- Platzbecker, Uwe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-11
- Volume
- 369
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2129338773
- Cited by
- 1,611
- References
- 42
- Citations by year
- 2026: 83 · 2025: 89 · 2024: 132 · 2023: 144 · 2022: 110 · 2021: 147 · 2020: 137 · 2019: 125 · 2018: 122 · 2017: 107 · 2016: 117 · 2015: 144 · 2014: 119 · 2013: 33
- FWCI
- 61.62
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- acute promyelocytic leukemia, all-trans retinoic acid, arsenic trioxide, idarubicin, induction therapy, consolidation therapy, maintenance therapy, event-free survival, overall survival, complete remission, hematologic toxicity, hepatotoxicity
- MeSH terms
- Arsenic Trioxide, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Arsenicals, Female, Humans, Male, Middle Aged, Neutropenia, Oxides, Thrombocytopenia, Tretinoin, Leukemia, Promyelocytic, Acute, Disease-Free Survival, Young Adult, Maintenance Chemotherapy, Induction Chemotherapy, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.